PROCEPT BioRobotics (PRCT)
(Delayed Data from NSDQ)
$71.70 USD
-0.61 (-0.84%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $71.70 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$71.70 USD
-0.61 (-0.84%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $71.70 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth C Momentum F VGM
Zacks News
Analysts Estimate PROCEPT BioRobotics Corporation (PRCT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
PROCEPT BioRobotics Corporation (PRCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intuitive Surgical, Inc. (ISRG) Stock Jumps 4.9%: Will It Continue to Soar?
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
PROCEPT BioRobotics Corporation (PRCT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
PROCEPT BioRobotics Corporation (PRCT) delivered earnings and revenue surprises of -5.66% and 0.33%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Integer (ITGR) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of 5.71% and 1.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
PROCEPT BioRobotics Corporation (PRCT) delivered earnings and revenue surprises of -8.51% and 17.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
PROCEPT BioRobotics Corporation (PRCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights TransMedics, PROCEPT BioRobotics and Sensus Healthcare
by Zacks Equity Research
TransMedics, PROCEPT BioRobotics and Sensus Healthcare are part of the Zacks top Analyst Blog Highlights.
3 Resilient Medical Stocks to Watch as Rate Hikes Continue
by Indrajit Bandyopadhyay
Here we discuss three Medical-Instruments stocks - TMDX, PRCT & SRTS - that continued to grow in the first nine months of 2022 even though three Fed rate hikes dragged broader indices down.